Synovus Financial’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-32,572
| Closed | -$4.18M | – | 942 |
|
|
2025
Q2 | $4.18M | Buy |
32,572
+416
| +1% | +$43.2K | 0.05% | 220 |
|
|
2025
Q1 | $2.85M | Buy |
32,156
+7,628
| +31% | +$744K | 0.04% | 282 |
|
|
2024
Q4 | $2.14M | Buy |
24,528
+481
| +2% | +$44.1K | 0.03% | 341 |
|
|
2024
Q3 | $2.22M | Buy |
24,047
+922
| +4% | +$91.6K | 0.03% | 354 |
|
|
2024
Q2 | $2.49M | Sell |
23,125
-7,796
| -25% | -$780K | 0.03% | 306 |
|
|
2024
Q1 | $2.93M | Sell |
30,921
-306
| -1% | -$26.2K | 0.04% | 279 |
|
|
2023
Q4 | $2.88M | Sell |
31,227
-8,971
| -22% | -$581K | 0.04% | 269 |
|
|
2023
Q3 | $2.02M | Sell |
40,198
-283
| -0.7% | -$15.1K | 0.02% | 334 |
|
|
2023
Q2 | $2.56M | Sell |
40,481
-2,632
| -6% | -$143K | 0.03% | 307 |
|
|
2023
Q1 | $1.94M | Sell |
43,113
-4,710
| -10% | -$212K | 0.02% | 338 |
|
|
2022
Q4 | $2.1M | Buy |
47,823
+13,466
| +39% | +$646K | 0.02% | 331 |
|
|
2022
Q3 | $2.26M | Buy |
34,357
+4,808
| +16% | +$309K | 0.03% | 298 |
|
|
2022
Q2 | $1.49M | Buy |
29,549
+2,826
| +11% | +$166K | 0.02% | 373 |
|
|
2022
Q1 | $1.7M | Buy |
26,723
+5,318
| +25% | +$382K | 0.02% | 356 |
|
|
2021
Q4 | $2.29M | Buy |
21,405
+219
| +1% | +$22.9K | 0.02% | 310 |
|
|
2021
Q3 | $2.17M | Buy |
21,186
+6,074
| +40% | +$566K | 0.02% | 294 |
|
|
2021
Q2 | $1.33M | Buy |
15,112
+790
| +6% | +$72.4K | 0.01% | 366 |
|
|
2021
Q1 | $1.39M | Buy |
+14,322
| New | +$1.43M | 0.02% | 317 |
|
|
2020
Q3 | – | Sell |
-63
| Closed | -$5K | – | 792 |
|
|
2020
Q2 | $5K | Hold |
63
| – | – | ﹤0.01% | 1311 |
|
|
2020
Q1 | $4K | Hold |
63
| – | – | ﹤0.01% | 1814 |
|
|
2019
Q4 | $5K | Hold |
63
| – | – | ﹤0.01% | 1303 |
|
|
2019
Q3 | $5K | Hold |
63
| – | – | ﹤0.01% | 1283 |
|
|
2019
Q2 | $6K | Hold |
63
| – | – | ﹤0.01% | 1190 |
|
|
2019
Q1 | $5K | Hold |
63
| – | – | ﹤0.01% | 1213 |
|
|
2018
Q4 | $3K | Hold |
63
| – | – | ﹤0.01% | 1263 |
|
|
2018
Q3 | $5K | Buy |
+63
| New | +$4.38K | ﹤0.01% | 1226 |
|
Other funds holding BPMC
IA
HNB
Synovus Financial's BPMC Position: Q3 2025 in Review
Synovus Financial sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 32,572 shares — an estimated $4.18M sold.
Synovus Financial first reported a position in BPMC in Q3 2018 and held it in 26 quarters. The position peaked at $4.18M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- Synovus Financial reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- Synovus Financial sold 32,572 Blueprint Medicines shares in Q3 2025, an estimated $4.18M.
- Synovus Financial first reported a position in Blueprint Medicines in Q3 2018 and held it in 26 quarters.
- Synovus Financial's Blueprint Medicines position peaked at $4.18M in Q2 2025.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on Synovus Financial's 13F filing for Q3 2025, filed 7 Nov 2025.